Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

Humana’s stock performance and market strategies continue to be closely monitored by investors and analysts, with particular attention to how the company navigates industry challenges.

UnitedHealth's dip offers long-term value, backed by strong fundamentals, rising dividends, and growth potential. Learn why ...

Raymond (NSE:RYMD) James has upgraded Humana’s stock rating from Market Perform to Outperform, setting a new price target of $315, citing the company’s strong performance and favorable drug mix.

Humana’s stock performance and market strategies continue to be closely monitored by investors and analysts, with particular attention to how the company navigates industry challenges. In other recent ...

By Shashwat Chauhan (Reuters) -As President Donald Trump's sweeping tax-cut and spending bill heads to the Senate, analysts ...

I’m 57 with a $1.5M home and a $400K rental with a 7.4% mortgage. I’m getting a $375K check soon. My financial adviser told ...

This was the stock's second consecutive day of losses.

On June 3, Bernstein SocGen Group analysts reiterated an ‘Outperform’ rating on Humana Inc. (NYSE: HUM) and a $313 price ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...